Navigation Links
KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals
Date:11/24/2009

The New York investment bank KTA Capital's client Neuren Pharmaceuticals Ltd (ASX:NEU) has agreed an AU$6.7 mil convertible note private placement with a U.S. institutional investor. The private placement was arranged by KTA Capital as Neuren's exclusive placement agent and advisor.

New York (PRWEB) November 23, 2009 -- The independent New York investment bank KTA Capital, LLC ("KTA Capital") has announced that its client Neuren Pharmaceuticals Ltd (ASX:NEU) ("Neuren") had entered into an AU$6.7 mil convertible note private placement agreement with a U.S. institutional investor. The private placement was arranged by KTA Capital as Neuren's exclusive placement agent and advisor. A copy of Neuren's public announcement can be found here:

http://www.asx.com.au/asxpdf/20091118/pdf/31m42b0gf6tn99.pdf

About KTA Capital, LLC

KTA Capital is an investment bank headquartered in New York, USA. Its services include international investment banking across a wide range of industries, both in the equity capital and debt markets, as well as M&A advisory. In its business it leverages its relationships with literally hundreds of institutional investors, including hedge funds, mutual funds, private equity funds, venture capital funds, bond funds, mezzanine debt funds, private placement funds, investment advisers, national, regional and international banks, acquisitive industry participants and strategic cornerstone investors, family offices, merchant banks and sovereign wealth funds. KTA Capital is registered as a broker-dealer with the United States Securities and Exchange Commission and is a member of Financial Industry Regulatory Authority, Inc. ("FINRA").

Media Contact:

Eugene Tablis
Tel.: +1 646 707 4177

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3253524.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

0

GOOD

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
4. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
5. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
7. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
8. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
9. Altheus Therapeutics Secures $3.6 Million in Venture Capital
10. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
11. Pharmasset Accesses up to $30 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving ... those living in larger cities are affected by air pollution related diseases. , That ... countries globally - decided to take action. , “I knew I had to take ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):